Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp > Neutropenia

<< Previous

Bullboard Posts

Next >>

Post by Metalsguy1on May 02, 2022 4:04pm

213 Views

Post# 34648843

Neutropenia

The Sernova trial is just as much at risk for this as well. Neutropenia is a side effect of the immunosuppressive drugs not the cells.The halt for neutropenia could have a crossover chilling effect on SVA stock price. Hopefully SVA has carefully dosed suppression and they better get their backsides in gear on the conformal coating. If they have a patient that goes neutropenic on such a small study we will be true bagholders until they get conformal coating in the clinic.

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”